Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hakan Gunaydin

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
ACS Medicinal Chemistry Letters|September 16, 2021
Structure-Based Discovery of Proline-Derived Arginase Inhibitors with Improved Oral Bioavailability for Immuno-OncologyMin Lu, Hongjun Zhang, Derun Li, et al.
Journal of Medicinal Chemistry|December 4, 2013
Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitorsZihao Hua, Howard Bregman, John L Buchanan, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Structure-Based Design of Potent and Selective CK1γ InhibitorsHongbing Huang, Lisa Acquaviva, Virginia Berry, et al.
Journal of Medicinal Chemistry|July 22, 2016
Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 InhibitorsErin F DiMauro, Stephen Altmann, Loren M Berry, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 1, 2024
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2Heike Schönherr, Pelin Ayaz, Alexander M Taylor, et al.
ACS Medicinal Chemistry Letters|December 21, 2016
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target EngagementIsaac E Marx, Thomas A Dineen, Jessica Able, et al.
Cancer Discovery|November 2, 2023
Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA MutationsAndreas Varkaris, Ferran Fece de la Cruz, Elizabeth E Martin, et al.
ACS Medicinal Chemistry Letters|March 25, 2017
Correction to "Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable <i>in Vivo</i> Target Engagement"Isaac E Marx, Thomas A Dineen, Jessica Able, et al.
Bioorganic & Medicinal Chemistry Letters|June 21, 2017
The discovery of benzoxazine sulfonamide inhibitors of Na<sub>V</sub>1.7: Tools that bridge efficacy and target engagementDaniel S La, Emily A Peterson, Christiane Bode, et al.
RSC Medicinal Chemistry|August 6, 2021
Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitorsAnmol Gulati, Charles S Yeung, Blair Lapointe, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
ACS Medicinal Chemistry Letters|September 16, 2021
Structure-Based Discovery of Proline-Derived Arginase Inhibitors with Improved Oral Bioavailability for Immuno-OncologyMin Lu, Hongjun Zhang, Derun Li, et al.
Journal of Medicinal Chemistry|December 4, 2013
Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitorsZihao Hua, Howard Bregman, John L Buchanan, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Structure-Based Design of Potent and Selective CK1γ InhibitorsHongbing Huang, Lisa Acquaviva, Virginia Berry, et al.
Journal of Medicinal Chemistry|July 22, 2016
Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 InhibitorsErin F DiMauro, Stephen Altmann, Loren M Berry, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 1, 2024
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2Heike Schönherr, Pelin Ayaz, Alexander M Taylor, et al.
ACS Medicinal Chemistry Letters|December 21, 2016
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target EngagementIsaac E Marx, Thomas A Dineen, Jessica Able, et al.
Cancer Discovery|November 2, 2023
Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA MutationsAndreas Varkaris, Ferran Fece de la Cruz, Elizabeth E Martin, et al.
ACS Medicinal Chemistry Letters|March 25, 2017
Correction to "Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable <i>in Vivo</i> Target Engagement"Isaac E Marx, Thomas A Dineen, Jessica Able, et al.
Bioorganic & Medicinal Chemistry Letters|June 21, 2017
The discovery of benzoxazine sulfonamide inhibitors of Na<sub>V</sub>1.7: Tools that bridge efficacy and target engagementDaniel S La, Emily A Peterson, Christiane Bode, et al.
RSC Medicinal Chemistry|August 6, 2021
Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitorsAnmol Gulati, Charles S Yeung, Blair Lapointe, et al.
Pageof 5